Case Report

Fluoroscopy-Guided Resolution of Ingested Thrombus Leading to Functional Disturbance of a Continuous-Flow Left Ventricular Assist Device

Jens Garbade, Hartmut B. Bittner, Friedrich-Wilhelm Mohr, and Markus J. Barten

Department of Cardiac Surgery, Heart Center Leipzig, University of Leipzig, Struempellstraße 39, 04289 Leipzig, Germany

Correspondence should be addressed to Jens Garbade, garbade@med.uni-leipzig.de

Received 28 August 2012; Accepted 23 September 2012

Academic Editors: N. A. Chowdri and P. De Nardi

Copyright © 2012 Jens Garbade et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

The third generation of left ventricular assist devices (LVADs) has been shown to improve outcome and quality of life in patients suffering from acute and chronic heart failure. However, VAD-associated complications are still a challenge in the clinical practice. Here we report the resolution of a mobile thrombus formation in the proximity of the inflow cannula of a third generation of LVADs (HVAD Pump, HeartWare, Inc.) in a patient with chronic heart failure 4 months after implantation.

1. Introduction

The development of continuous-flow left ventricular assist devices evolved from an unacceptable, nonviable strategy to a proven and adopted treatment for patients with end-stage heart failure [1]. Despite this increased adoption, chronic support may have a higher rate of device-related thromboembolic complications and this is associated with significant morbidity and mortality [2, 3]. The event rates quoted for LVAD thromboembolism vary considerably from 1.1 to 34.8% between devices [4]. Therefore, patient adherence and education are mandatory to ensure sufficient anticoagulation according to the current recommendations. Severe pump thrombosis is a relatively rare complication and therapeutic experience is limited. The application of systemic thrombolytics with axial and centrifugal flow pumps has been described in the past [5, 6]. In this paper we describe the application of intraventricular thrombolitics in a third-generation centrifugal flow pump. The HVAD Pump (HeartWare, Inc.) is a miniaturized, continuous-flow device that is completely implanted within the pericardial space for uni- and possible biventricular support [7, 8]. The recommended target international-normalized ratio (INR) is 1.7 to 2.3 in addition to antiplatelet therapy.

Here we describe the resolution of a significant thrombus formation in the proximity of the inflow cannula of a HVAD Pump with intra-ventricular fluoroscopy-guided local lysis.

2. Case Presentation

A 60-year-old man (body weight 81 kg) was admitted to our institution for further heart failure therapy. However, the patient was eligible for transplantation and listed as high urgent. Due to recurrent incurable ventricular arrhythmias and catecholamine support an LVAD was implanted. The patient received an LVAD (HVAD Pump, HeartWare) continuous-flow pump. The postoperative course was uneventful and the patient was discharged 30 days after implantation. Four months later, the patient developed signs of heart failure and the controller displayed technical problems with the assist device.

Clinically, the patient exhibited worsening shortness of breath and signs of hemolysis (dark red urine), and, additionally, an audible sound was detected from the pump. At the time of admission the patient’s anticoagulation status was subtherapeutic (INR 1.3 and PTT 45 sec), so a heparin-bolus of 10,000 IE was given immediately, followed by continuous
intravenous heparin administration to achieve a therapeutic
PTT range of 80 to 100 sec. Initially, the pump speed was
2500 rpm with an estimated flow of up to 9 L/min and an
abnormal increase in power consumption. Laboratory results
showed evidence of severe hemolysis, for example, increase
of bilirubin and LDH. Waveform downloads from the assist
device, combined with reduced flow pattern and increased
power requirement over time, suggested an obstruction of
the inflow cannula. Table 1 summarizes all relevant clinical-
and device-associated data. Transthoracic echocardiography
revealed reduced left ventricular function, moderate mitral
regurgitation, intermittent aortic valve opening, and good
right ventricular function. The septum had a normal
position without any signs of suction suggesting a normal
position of the left ventricle cannula. Additionally, the echo
revealed a large thrombus formation obstructing the inflow
cannula, resulting in partial occlusion. Subsequently, the
patient was referred to our cath-lab for fluoroscopy-guided
direct inflow cannula lysis. The LV was accessed via the right
femoral artery using a 5-French pigtail catheter. The pigtail
catheter was placed under fluoroscopic guidance directly
into the proximity of the inflow-cannula. Additionally it was
very important to avoid any ingestion of the catheter into
the pump (Figure 1). Twenty-seven mg of alteplase (Actilyse)
was administered at a rate of 1 mg/min under fluoroscopic
guidance. Within 27 minutes of selective thrombolysis,
energy consumption decreased to normal values from 15
to 4.0 watts and also the pump flow reached normal range
(Table 1). The procedure was tolerated well without any
bleeding complications. After removal of the catheter the
femoral artery sealed with a closure device (AngioSeal), and
the patient returned to the ICU.

The subsequent clinical course was uneventful and
the pump continued to function well. After achieving an
adequate anticoagulation status (INR 2 to 2.5) the patient
was discharged home 5 days after intervention.

### 3. Discussion

Assist device-associated complications are challenging prob-
lems in treating patients with mechanical circulatory sup-
port. The incidence of thrombus formation depends on
anticoagulation status, type of mechanical support, and
patient adherence [1]. Increased or sudden changes of pump
parameters are evidence of potential complications. Despite
the considerable advances in device technology, monitoring
and management of the hypercoagulable status—resulting
from foreign surfaces of the assist device system, altered
rheologic conditions, and blood stasis in the patient—
remain a challenge [4]. Anticoagulation with warfarin and
often additionally with antiplatelet therapy exposes the
patient to an increased risk of bleeding. This situation could

### Table 1: HVAD parameters and laboratory data over the time (anticoagulation and hemolysis).

|                | Speed (RPM) | Flow (LPM) | Power (Watts) | INR  | PTT (sec) | Total Bilirubin (mg/dL) | LDH (U/L) |
|----------------|-------------|------------|---------------|------|-----------|------------------------|-----------|
| Prior thrombus | 2600        | 5.4        | 4             | 2.2  | 50        | 0.98                   | 367       |
| Admission      | 2600        | up to 12.0 | up to 15.0    | 1.3  | 45        | 3.53                   | 4478      |
| Heparinization | 2500        | up to 9.0  | 5.0–10.0      | 1.7  | 117       | 4.49                   | 6420      |
| LV-lysis       | 2500        | 4.0        | 4.0           | 1.5  | 139       | 3.56                   | 5676      |
| Discharge      | 2500        | 4.5        | 4.5           | 2.2  | 41        | 0.77                   | 1194      |
| Followup       | 2600        | 5.0        | 5.0           | 2.3  | 49        | 0.63                   | 378       |

INR: international normalized ratio; PTT: partial thromboplastin time; LDH: lactate dehydrogenase.
exacerbate by alterations in kidney and liver function or by the nonadherence of the patient to follow the therapeutic anticoagulation recommendations. On the other hand, VAD-associated thromboembolic occurrences may also result in life-threatening complications. In case of severe VAD thrombosis leading to an acute irreversible pump stoppage a surgical intervention is required but often results in a high mortality and morbidity [2]. In milder case of VAD thrombosis medical or interventional therapy as systemic and local catheter-based thrombolysis has been reported as alternative approaches with variable outcome previously [4–6].

Here we described the resolution of a thrombus formation in the proximity of the inflow cannula of the HVAD continuous-flow assist device. Compared to open reexploration or systemic thrombolysis, the fluoroscopy-guided selective administration of fibrinolytic agents allows a dose reduction of these agents, and, therefore, to reduce the potential risk for general severe bleeding complications.

Our paper indicates that the intracavitary lysis of thrombus-mediated inflow cannula obstruction of the HVAD pump may be an effective and safe concept. However, for out-hospital care and successful mechanical support, a stringent patient adherence, monitoring, and education are mandatory to avoid any complications, especially thromboembolic events.

**Consent**

Written informed consent was obtained from the patient for the publication of this paper and any accompanying images.

**Acknowledgment**

The authors have no financial associations or relationship with industry that might pose a conflict of interest with the submitted manuscript.

**References**

[1] M. S. Slaughter, J. G. Rogers, C. A. Milano et al., “Advanced heart failure treated with continuous-flow left ventricular assist device,” *New England Journal of Medicine*, vol. 361, no. 23, pp. 2241–2251, 2009.

[2] S. Brush, D. Budge, R. Alharethi et al., “End-of-decision making and implementation in recipients of a destination left ventricular assist device,” *Journal of Heart and Lung Transplantation*, vol. 29, no. 12, pp. 1337–1341, 2010.

[3] W. L. Holman, W. E. Pae, J. J. Teutenberg et al., “INTERMACS: interval analysis of registry data,” *Journal of the American College of Surgeons*, vol. 208, no. 5, pp. 755–761, 2009.

[4] Y. Wadia, P. Thiagarajan, R. Delgado, P. Allison, K. Robertson, and O. H. Frazier, “Antiphospholipid syndrome with antiprothrombin autoantibodies in a patient with an axial-flow left ventricular assist device,” *Journal of Heart and Lung Transplantation*, vol. 24, no. 8, pp. 1133–1136, 2005.

[5] R. Delgado, O. H. Frazier, T. J. Myers et al., “Direct thrombolytic therapy for intraventricular thrombosis in patients with the Jarvik 2000 left ventricular assist device,” *Journal of Heart and Lung Transplantation*, vol. 24, no. 2, pp. 231–233, 2005.

[6] V. Ninios, A. Visouli, and A. Pitsis, “Repeated successful thrombolysis of a Jarvik 2000 left ventricular assist device in a patient with noncompaction cardiomyopathy,” *Circulation*, vol. 121, no. 3, pp. e13–e14, 2010.

[7] G. M. Wieselthaler, G. O’Driscoll, P. Jansz, A. Khaghani, and M. Strueber, “Initial clinical experience with a novel left ventricular assist device with a magnetically levitated rotor in a multi-institutional trial,” *Journal of Heart and Lung Transplantation*, vol. 29, no. 11, pp. 1218–1225, 2010.

[8] R. Hetzer, T. Krabatsch, A. Stepanenko, E. Hennig, and E. V. Potapov, “Long-term biventricular support with the heartware implantable continuous flow pump,” *Journal of Heart and Lung Transplantation*, vol. 29, no. 7, pp. 822–824, 2010.